What should and should not be covered in intraabdominal infection;Lo que hay que cubrir y lo que no hay que cubrir en la infección intraabdominal

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue SUPPL. 2, 2010, Pages 32-41

  Guirao, Xavier ^a  

^a HOSPITAL GENERAL DE GRANOLLERS   (Spain)

Author keywords

Appropriateness of empirical antibiotic therapy; Intrabdominal infection; Risk factors of antibiotic treatment failure

Indexed keywords

ANTIBIOTIC AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; ARTICLE; DISEASE ASSOCIATION; HUMAN; PATHOGENESIS; RISK; TREATMENT FAILURE;

ABDOMEN; ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; CANDIDIASIS, INVASIVE; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DECISION TREES; DRUG RESISTANCE, MICROBIAL; HUMANS; INTENSIVE CARE; PERITONITIS; PSEUDOMONAS INFECTIONS; RISK; SEPSIS; SEVERITY OF ILLNESS INDEX; UNNECESSARY PROCEDURES;

EID: 79551513653     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(10)70028-8     Document Type: Article

References (90)

1. P. Barie, L. Hydo, and S. Eachempati Longitudinal Outcomes of Intra-abdominal Infection Complicated by Critical Illness Surg Infect 5 2004 365 373
2. H. Boucher, G. Talbot, J. Bradley, J. Edwards, D. Gilbert, and L. Rice Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
3. K. Kanetake, M. Hayashi, A. Hino, N. Futamura, Y. Mori, and H. Takagi Primary peritonitis associated with streptococcal toxic shock-like syndrome: Report of a Case Surg Today 34 2004 1053 1056
4. D. Mosdell, D. Morris, A. Voltura, D. Pitcher, M. Twiest, and R. Milne Antibiotic treatment for surgical peritonitis Ann Surg 214 1991 543 549
5. J. Tellado, S. Sen, M. Caloto, R. Kumar, and G. Nocea Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community acquired intra-abdominal infections in Spain Scand J Infect Dis 39 2007 947 955
6. A. Sitges-Serra, J. Sancho-Isenser, E. Membrilla, and M. Girvent Grupo de estudio PEPES (Patógenos emergentes en peritonitis). Estudio de adecuación de la antibioticoterapia empírica en el tratamiento de la infeción intraabdominal complicada XXVII Congreso Nacional de Cirugía Madrid 2008
7. P. Montravers, R. Gauzit, C. Muller, J. Marmuse, A. Fichelle, and J. Desmonts Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy Clin Infect Dis 23 1996 486 494
8. A. Roehrborn, L. Thomas, O. Potreck, C. Ebener, C. Ohmann, and P. Goretzki The microbiology of postoperative peritonitis Clin Infec Dis 33 2001 1513 1519
9. J. Chow, V. Satishchandran, T. Snyder, C. Harvey, I. Friedland, and M. Dinubile In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART) Surg Infect 6 2006 439 447
10. D. Paterson, F. Rossi, F. Baquero, P. Hsuech, G. Woods, and V. Satishchandran In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART) J Antimicrob Chemother 55 2005 965 973 (Pubitemid 40883183)
11. F. Rossi, F. Baquero, P. Hsuech, D. Paterson, G. Bochicchio, and T. Snyder In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends) J Antimicrob Chemother 58 2006 205 210 (Pubitemid 44295010)
12. P. Montravers, A. Lepape, L. Dubreuil, R. Gauzit, Y. Pean, and D. Benchimol Clinical and microbiolocal profiles and community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study J Antimicrob Chemother 63 2009 785 794
13. Members of the American College of Chest Pysicians, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
14. M. Rangel-Fausto, D. Pittet, M. Costigan, T. Hwang, C. Davis, and R. Wenzel The natural history of SIRS JAMA 273 1995 117 123
15. X. Guirao, G. Franch, J. Navinés, M. Casal, M. Juvany, and J. Montero Monitorización de la proteína C-reactiva en el diagnóstico precoz de las complicaciones mayores en la cirugía colorrectal electiva XXVII Congreso Nacional de Cirugía Madrid. 2008
16. E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, and B. Knoblich Early goaldirected therapy Iin the treatment of severe sepsis and septic shock N Engl J Med 345 2001 1368 1377
17. M. Mikkelsen, A. Miltiades, D. Gaieski, M. Goyal, B. Fuchs, and C. Shah Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock Crit Care Med 37 2009 1670 1777
18. H. Nguyen, E. Rivers, G. Moan, E. Abraham, S. Trzeciak, and D. Huang Review of the literature and emergency department management guidelines Ann Emerg Med 48 2006 28 54
19. N. Christou, P. Barie, P. Dellinger, P. Waymack, and H. Stone Surgical infection society intra-abdominal infection study. Prospective evaluation of management techniques and outcome Archives of Surgery 128 1993 193 199
20. H. Wacha, T. Hau, R. Dittmer, C. Ohmann the Peritonitis Study Group Risk factors associated with intraabdominal infections: a prospective multicenter study Lagenbeck's Arch Surg 384 1999 24 32
21. K. Bosscha, K. Reijnders, P. Hulstaert, A. Algra, and C. Van der Werken Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis British Journal of Surgery 84 1997 1532 1534
22. F. Álvarez-Lerma Modification of empiric antibiotic treatment in patients with penumonia acquired in the intensive care unit. ICY-Acquired Pneumonia Study Group Intensive Care Med 22 1996 387 394
23. M. Kollef, G. Sherman, S. Ward, and V. Fraser Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically Ill patients Chest 115 1999 462 474
24. C. Luna, A. Famiglietti, R. Absi, A. Videla, F. Nogueira, and A. Fuenzalida Community-acquired pneumonia Chest 118 2000 1344 1354
25. E. Ibrahim, G. Sherman, S. Ward, V. Frase, and M. Kollef The influence of inadequate antimicrobial treatment of bloodstream infections on patients outcomes in the ICU setting Chest 118 2000 146
26. K. Krobot, D. Yin, Q. Zhang, S. Sen, A. Altendorf-Hofmann, and J. Scheele Effect of inappropiate initial empiric antibiotic therapy on outcome of patients with community-acquiered intrabdominal infections requiring surgery Eur J Clin Microbiol Infec Dis 23 2004 682 687
27. M. Baré, X. Castells, A. García, M. Riu, M. Comas, and M. Gil-Egea Importance of apropiateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections Int J Technol Assess Health Care 22 2006 242 248
28. D. Battelmen, M. Callahan, and H. Thaler Rapid antibiotic delivery and appropiate antibiotic selection reduce lenght of hospital stay of patients with community-acquired pneumonia Arch Intern Med 162 2002 682 688
29. M. Sturkenboom, W. Goettsch, G. Picelli, B. Veld, D. Yin, and R. De Jong Inappropiate initial treatment of secondary intra-abdomial infections leads to increased risk of clinical failure and costs Br J Clin Pharmacol 60 2005 438 443
30. H. Dupont, C. Carbon, J. Carlet Severe Generalized Perintonits Study Group T Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalizaed peritonitis: a multicenter randomized controlled trial Antimicrob Agents Chemother 44 2000 2028 2033
31. A. Mansour, W. Watson, V. Shayani, and J. Pickelman Abdominal operation in patients with cirrhosis: still a major surgical challenge Surgery 122 1997 730 735
32. M. Falagas, L. Barefoot, J. Griffith, R. Ruthzar, and D. Snydman Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections Eur J Clin Microbiol Infec Dis 15 1996 913 921
33. J. Tellado, A. Sitges-Serra, F. Barcenilla, M. Palomar, R. Serrano, and J. Barberán Pautas de tratamiento antibiótico empírico de las infecciones intraabdominales Rev Esp Quimioterap 18 2005 2
34. A. Sitges-Serra, M. López, M. Girvent, S. Almirall, and J. Sancho Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis Br J Surg 89 2002 361 367
35. M. Gobernado Infecciones por bacterias productoras de β-lactamasas X. Guirao Garriga, J.A. Díaz, Infecciones quirúrgicas 2006 Arán Editores Madrid 483 486
36. F. Baquero, P. Hsuech, D. Paterson, F. Rossi, G. Biochicchio, and G. Gallagher In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART) Surg Infect (Larchmt) 10 2009 99 104
37. T. Coque, F. Baquero, and R. Cantón Increasing prevalence of ESBL-producing enterobacteriacea in Europe Eurosurveillance 13 2008 1 11
38. F. Baquero, E. Cercenado, R. Cisterna, M. De la Rosa, J. García-Rodríguez, and M. Gobernado Patrones de sensiblidad a antimicrobianos e Enterobacterias causantes de infecciones intrabdominales en España: resultados del estudio SMART 2003 Rev Esp Quimioterap 19 2006 51 59
39. J. Rodríguez-Baño, and D.L. Paterson A change in the epidemiology of infections due to extended-spectrum β-lactamase-producing organisms Clin Infect Dis 42 2006 935 937 Epub 2006 Feb 27
40. R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, and F. Baquero Prevalence and spread of extended-spectrum b-lactamase-producing Enterobacteriaceae in Europe Clin Microbiol Infect 14 Suppl 1 2008 144 153
41. J. Rodríguez-Baño, and M. Navarro Impacto de las BLEE en los tratamientos empíricos y las políticas antibióticas Enferm Infecc Microbiol Clin 25 Supl 2 2007 54 59
42. S. Bratu, D. Landman, R. Haag, R. Recco, A. Eramo, and M. Alam Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium Arch Intern Med 165 2005 1430 1435
43. D. Gülmez, N. Woodford, M. Pelepou, S. Musthaq, G. Metan, and Y. Yakupogullari Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss Int J Antimicrob Agents 31 2008 523 526
44. I. Skippen, M. Shemko, J. Turton, M. Kaufmann, C. Palmer, and N. Shetty Epidemiology of infections caused by extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case control study from a tertiary hospital in London J Hosp Infect 64 2006 115 123
45. J. Martínez, J. Aguilar, M. Almela, F. Marco, A. Soriano, and F. López Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase- producing Escherichia coli or Klebsiella spp. in patients with bacteraemia J Antimicrob Chemother 58 2006 1082 1085 Epub 2006 Sep 1.
46. M. Tumbarello, T. Spanu, M. Sanguinetti, R. Citton, E. Montuori, and F. Leone Bloodstream infections caused by extended-spectrum-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome Antimicrob Agents Chemother 50 2006 498 504
47. R. Ben-Ami, J. Schwaber, S. Navon-Venezia, D. Schwartz, I. Chmelnitsky, and A. Leavitt Influx of extended-spectrum β-lactamase-producing enterobacteriaceae into the hospital Clin Infect Dis 42 2006 925 934
48. R. Colodner, W. Rock, B. Chazan, N. Keller, N. Guy, and W. Sakran Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients Eur J Clin Microbiol Infect Dis 23 2004 163 167
49. C. Peña, C. Gudiol, F. Tubau, M. Saball, M. Pujol, and M. Domínguez Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients Clin Microbiol Infect 12 2006 279 284
50. B. Swenson, R. Metzger, T. Hedrick, S. McElearney, H. Evans, and R. Smith Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"? Surg Infect (Larchmt) 10 2009 29 39
51. M. DiNubile, I. Friendland, C. Chan, M. Motyl, H. Giezel, and M. Shivaprakash Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy Eur J Clin Microbiol Infect Dis 24 2005 443 449
52. A. Harris, J. McGregor, J. Johnson, S. Strauss, A. Moore, and H. Standiford Risk factors for colonization with extended-spectrum β-lactamase- producing bacteria and intensive care unit admission Emerg Infect Dis 13 2007 1144 1149
53. C. Kang, S. Kim, W. Park, K. Lee, H. Kim, and E. Kim Boodstream infections caused by antibiotic-resistans gram-negative bacilli: risk factors and impact of inappropiate initial antimicrobial therapy on outcome Antimicrob Agents Chemother 49 2005 760 766
54. D. Raymond, S. Pelletier, T. Crabtree, H. Evans, T. Pruett, and R. Sawyer Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients Crit Care Med 31 2003 1035 1041
55. D. Genné, A. Menetrey, P. Indino, C. Sénéchaud, and H.H. Siegriest Treatment of secondary peritonitis: is a less expensive broad-spectrum antibiotic as effective as a carbapenem? Dig Surg 20 2003 415 420
56. A. Sotto, J. Lefrant, P. Fabbro-Peray, L. Muller, J. Tafuri, and F. Navarro Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis J Antimicrob Chemother 50 2002 569 576
57. J. Bradley, J. Garau, K. Roston, and J. Qujinn Carbapenems in clinical practice: a guide to the use in serious infection Int J Antimicrob Agents 11 1999 93
58. S. Kusachi, Y. Sumiyama, Y. Arima, Y. Yoshida, H. Tanaka, and Y. Nakamura Isolated bacteria and drug susceptibility associated with the course of surgical site infections J Infect Chemother 13 2007 166
59. T. Babinchak, E. Ellis-Grose, N. Dartois, G. Rose, E. Loh Tigecycline 301 and 306 Study G The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data Clin Infect Dis 41 2005 S354 S366
60. H. Dupont The empiric treatment of nosocomial intra-abdominal infections Int J Infec Dis 11 Suppl 1 2007 S1 6
61. R. Burnett, D. Haverstock, E. Dellinger, H. Reinhart, J. Bohnen, and O. Rotstein Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial Surgery 118 1995 716 723
62. A. Onderdonk, J. Barlett, T. Louie, N. Sullivan-Seigler, and S. Gorbach Microbial synergy in experimental intra-abdomninal abscess Infec Immun 13 1976 22 26
63. R. Moellering Enterococcus species, Streptococcus bovis, and Leuconostoc species E.C. Livingstone, Mandel, Douglas, and Bennett 2005 Principles and Practice of Infectious Diseases Philadelphia 2411 2421
64. R. Dahms, E. Johnson, C. Statz, J. Lee, D. Dunn, and G. Beilman Third-generation cephalosporins and vancomycin as risk factors for postorpeative vancomycin-resistant enterococcus infection Arch Surg 133 1998 1343 1346
65. A. Röhrborn, H. Wacha, U. Schöffel, A. Billing, P. Aeberhard, and B. Beghard Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial Surg Infect 1 2000 95 107
66. J. Solomkin, A. Yellin, O. Rostein, N. Christou, E. Dellinger, and J. Tellado Ertapenem versus piperacillin-tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comprative phase III trial Ann Surg 237 2003 235 245
67. S. Borbone, C. Cascone, M. Santagati, M. Mezzatesta, and M. Stefani Bactericidal activity of ertapenem against major intra-abdominal pathogens Int J Antimicrob Agents 28 2006 396 401
68. N. Namias, J. Solomkin, E. Jensen, J. Tomassini, and M. Abramson Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra- abdominal infections in hospitalized adults Surg Infect 8 2007 15 28
69. P. Barie, S. Vogel, E. Dellinger, O. Rostein, J. Solomkin, and J. Yang A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group Arch Surg 132 1997 1294 1302
70. K. Itani, S. Wilson, S. Award, E. Jensen, T. Finn, and M. Abramson Ertapenem versus cefotetan prophylaxis in elective colorectal surgery N Engl J Med 355 2006 2640 2651
71. B. Mirelis Otero, and G. Prats Pastor Conceptos de microbiología aplicada X. Guirao Garriga, Infecciones Quirúrgicas 2006 Arán Madrid 27 46
72. H. Boucher, C. Wennersten, and G. Eliopoulos In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria Antimicrob Agents Chemother 44 2000 2225 2229
73. C. Betriu, I. Rodríguez-Avial, B. Ali-Sánchez, M. Gómez, J. Álvarez, and J. Picazo In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain Antimicrob Agents Chemother 46 2002 892 895
74. D. Dean, and K. Buechard Fungal Infections in Surgical Patients Am J Surg 171 1996 374 382
75. J. Nolla-Salas, A. Sitges-Serra, C. León-Gil, J. Martínez-Gonzalez, M. León-Regidor, and P. Ibáñez- Lucia Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy Intensive Care Med 23 1997 23 30
76. P. Sandven, K. Giercksky the NORGAS Group, and the Norweigian Yeast Study Group Yeast colonization in surgical patients with intra-abdominal perforations Eur J Clin Microbiol Infect Dis 20 2001 475 481
77. C. León, S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, and F. Álvarez-Lerma A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization* Crit Care Med 34 2006 730 737
78. J. Vincent, E. Anaissie, H. Bruining, W. Demajo, M. El-Ebiary, and J. Haber Epidemiology, diagnosis and treatment od systemic Candida infection in surgical patients under intensive care Intensive Care Med 24 1998 206 216
79. C. Weiss III., C. Statz, R. Dahms, M. Remucal, and D.G.B.J. Dunn Six years of surgical wound infection surveillance at a tertiary care center: review of the microbiologic and epidemiological aspects of 20,007 wounds Arch Surg 134 1999 1041 1048
80. M. Levison, and D. Zeigler Correlation of APACHE II score, drainage technique and outcome in postoperative intra-abdominal abscess Surg Gynecol Obstet 172 1991 89 94
81. R. Brolin, L. Flancbaum, F. Ercoli, L. Milgrim, J. Bocage, and A. Blum Limitations of percutaneous catheter drainage of abdominal abscesses Surg Gynecol Obstet 173 1991 203 210
82. P. Montravers, H. Dupont, R. Gauzit, B. Veber, C. Auboyer, and P. Blin Candida as a risk factor for mortality in peritonitis Crit Care Med 34 2006 646 652
83. N. Pultz, U. Stiefel, M. Ghannoum, M. Helfand, and C. Dosnkey Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice Antimicrob Agents Chemother 49 2005 438 440
84. British Society for Antimicrobial Chemotherapy Management of deep Candida infection in surgical and intensive care unit patients Intensive Care Med 20 1994 522 528
85. S. Blot, K. Vandewoude, and J. Waele Candida peritonitis Curr Opin Crit Care 13 2007 195 199
86. J. Nolla-Salas, J. Torres-Rodríguez, S. Grau, F. Isbert, T. Torrella, and M. Riveiro Succesful treatment with liposomal amphoitercin B of an intraabdominal abscess due to Candida norvegensis associates with a gore-tex-mesh infection Scand J Infect Dis 32 2000 560 562
87. G. Pier, and R. Ramphal Pseudomonas aeruginosa G. Mandell, J. Bennet, R. Dolin, Mandell, Douglas and Bennett's. Principles and practice of infectious diseases 2005 Elsevier Churchill Livingstone Philadelphia 2587 2615
88. C. Kang, S. Kim, H. Kim, S. Park, Y. Choe, and M. Oh Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome Clin Infect Dis 37 2003 745 751
89. P. Berthelot, F. Grattard, P. Mahul, R. Jospé, C. Venet, and A. Carricajo Prospective study of nosocomial colonization and infection due to Pseudomonas aeruginosa in mechanically ventilated patients Intensive Care Med 27 2001 503 512
90. A. Kumar, D. Roberts, K. Wood, B. Light, J. Parrillo, and S. Sharma Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 34 2006 1589 1596